AliveCor Inc.
AliveCor Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at AliveCor Inc..
AliveCor Inc. is a company.
Key people at AliveCor Inc..
Key people at AliveCor Inc..
AliveCor Inc. is a medical device and AI company that develops FDA-cleared ECG hardware and software for consumer mobile devices, enabling remote heart rhythm monitoring and detection of arrhythmias like atrial fibrillation.[1][2][4] Its flagship Kardia products, including the KardiaMobile 6L (world's first 6-lead personal ECG) and the 2024-launched Kardia 12L (AI-powered handheld 12-lead system detecting 35 cardiac conditions), serve consumers, healthcare providers, health systems, employers, and OEM wearable partners by solving the problem of inaccessible, medical-grade cardiac diagnostics outside clinical settings.[1][2][4][5] The company addresses cardiovascular disease—a leading global cause of death—through portable, AI-driven tools that deliver actionable heart data, with over 250 million ECGs recorded and subscriptions like KardiaCare for ongoing monitoring and coaching.[2][4]
AliveCor's growth momentum includes expansions like AliveCor Labs (2021 diagnostic facility), KardiaComplete (2022 enterprise service bundling ECG and blood pressure monitoring), and OEM integrations for wearables, positioning it as a leader in personal and remote cardiology with strong clinical validation and provider adoption.[1][3][5]
AliveCor was co-founded in 2011 by David Albert, a medical doctor and former chief clinical scientist of cardiology at General Electric, alongside scientists Bruce Satchwell and Kim Barnett, and is headquartered in Mountain View, California.[1] Albert's idea stemmed from decades of innovation: in 1990, he began developing ECGs for handheld computers like Hewlett-Packard's first palmtop, leading to a 1998 patent for wireless ECG transmission in portable devices.[1] This vision evolved into consumer-friendly products, starting with early Kardia devices and gaining traction through FDA clearances, such as the single-lead KardiaMobile and the 2021 credit-card-sized KardiaMobile Card.[1][4] Pivotal moments include the 2020 launch of KardiaCare subscriptions and 2024's dual FDA clearance for KAI 12L AI and Kardia 12L, marking breakthroughs in AI-detected heart attacks via reduced leadsets.[1][2]
AliveCor rides the remote patient monitoring and AI cardiology wave, capitalizing on post-pandemic demand for home-based diagnostics amid rising cardiovascular disease prevalence.[3][5] Timing aligns with wearable tech proliferation and AI advancements, enabling OEM partnerships (e.g., turnkey ECG for Android wearables) and disrupting traditional 12-lead ECGs limited to clinics.[2][3] Market forces like FDA clearances for consumer devices, reimbursement for services, and clinician shortages favor its scalable solutions, which accelerate time-to-action and enhance efficiency for health systems managing millions of patients.[5] By influencing ecosystems through APIs, SDKs, and integrations, AliveCor bridges consumer wearables to professional care, standardizing AI-validated heart data and filling gaps in ambulatory monitoring.[3][6]
AliveCor is poised to dominate AI cardiology with expansions in enterprise platforms, OEM wearables, and global clinical trials, leveraging its 2024 Kardia 12L as a care-pathway disruptor.[2][3] Trends like AI multimodal diagnostics (e.g., combining ECG with BP/genomics) and value-based care will propel growth, especially as regulations evolve for direct-to-consumer AI health tools. Its influence may evolve from personal monitoring pioneer to ecosystem orchestrator, powering insurer programs and telehealth, ultimately making medical-grade cardiology ubiquitous and reducing heart disease burdens worldwide—echoing founder Albert's handheld vision now supercharged by AI.
